EA200000629A1 - Стабилизированные растворы терипаратида - Google Patents

Стабилизированные растворы терипаратида

Info

Publication number
EA200000629A1
EA200000629A1 EA200000629A EA200000629A EA200000629A1 EA 200000629 A1 EA200000629 A1 EA 200000629A1 EA 200000629 A EA200000629 A EA 200000629A EA 200000629 A EA200000629 A EA 200000629A EA 200000629 A1 EA200000629 A1 EA 200000629A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stabilized
teriparatid
solutions
cresol
preservative
Prior art date
Application number
EA200000629A
Other languages
English (en)
Other versions
EA004761B1 (ru
Inventor
Чин-Минг Чанг
Генри А. Хейвел
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000629(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200000629A1 publication Critical patent/EA200000629A1/ru
Publication of EA004761B1 publication Critical patent/EA004761B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)

Abstract

(57) Описана стабилизированная фармацевтическая композиция с паратиреоидным гормоном в виде раствора для парентерального введения, в которой терапевтически активный ингредиент стабилизирован буфером и полиолом. Предпочтительные препараты содержат в водном растворе РТН (1-34) человека, маннитол, ацетатный или тартратный буферный агент и м-крезол или бензиловый спирт в качестве консерванта.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000629A 1997-12-09 1998-12-08 Стабилизированная жидкая композиция паратиреоидного гормона, флакон с композицией и способы их получения EA004761B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09
PCT/US1998/026043 WO1999029337A1 (en) 1997-12-09 1998-12-08 Stabilized teriparatide solutions

Publications (2)

Publication Number Publication Date
EA200000629A1 true EA200000629A1 (ru) 2000-12-25
EA004761B1 EA004761B1 (ru) 2004-08-26

Family

ID=22086574

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000629A EA004761B1 (ru) 1997-12-09 1998-12-08 Стабилизированная жидкая композиция паратиреоидного гормона, флакон с композицией и способы их получения

Country Status (32)

Country Link
EP (2) EP0920873B1 (ru)
JP (1) JP4405666B2 (ru)
KR (1) KR100482703B1 (ru)
CN (1) CN1198644C (ru)
AR (1) AR018526A1 (ru)
AT (1) ATE260113T1 (ru)
AU (1) AU759726B2 (ru)
BR (1) BR9813463A (ru)
CA (1) CA2314313C (ru)
CY (1) CY1114000T1 (ru)
CZ (1) CZ302401B6 (ru)
DE (1) DE69821872T2 (ru)
DK (2) DK0920873T3 (ru)
EA (1) EA004761B1 (ru)
EG (1) EG23675A (ru)
ES (2) ES2215268T3 (ru)
HK (1) HK1021798A1 (ru)
HU (1) HU230784B1 (ru)
ID (1) ID27741A (ru)
IL (1) IL136662A (ru)
MY (1) MY120063A (ru)
NO (1) NO327302B1 (ru)
NZ (1) NZ505222A (ru)
PE (1) PE20000001A1 (ru)
PL (1) PL194268B1 (ru)
PT (2) PT920873E (ru)
SK (1) SK288203B6 (ru)
TR (1) TR200002134T2 (ru)
TW (1) TW570811B (ru)
UA (1) UA72884C2 (ru)
WO (1) WO1999029337A1 (ru)
ZA (1) ZA9811127B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
AU785444B2 (en) * 2000-05-19 2007-06-14 Jefferson Pharmaceuticals, Llc Peptide pharmaceutical formulations
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2003039331A2 (en) * 2001-11-05 2003-05-15 Eli Lilly And Company Method for improving stability of a bone-connecting implant
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
KR101105486B1 (ko) 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
JP4871124B2 (ja) 2003-06-20 2012-02-08 アレス トレーディング ソシエテ アノニム 凍結乾燥ｆｓｈ／ｌｈ製剤
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
RU2421238C2 (ru) 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
RU2484086C9 (ru) 2003-12-23 2013-08-20 Инфинити Дискавэри, Инк. Аналоги бензохинонсодержащих ансамицинов (варианты), способ их получения, фармацевтическая композиция (варианты) и способ лечения рака (варианты)
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
KR101512377B1 (ko) 2006-10-03 2015-04-28 라디우스 헬쓰, 인코포레이티드 골 아나볼릭 단백질을 위한 약물 전달 방법
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
MX2009010808A (es) * 2007-04-12 2009-10-29 Infinity Discovery Inc Formulaciones de ansamicina de hidroquinona.
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
AU2009228093B2 (en) 2008-03-28 2014-08-07 Neurelis, Inc. Administration of benzodiazepine compositions
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
JPWO2011030774A1 (ja) * 2009-09-09 2013-02-07 旭化成ファーマ株式会社 １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
IL310069A (en) 2015-04-29 2024-03-01 Radius Pharmaceuticals Inc Cancer treatment methods
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
JP7059195B2 (ja) 2016-03-01 2022-04-25 アセンディス ファーマ ボーン ディジージズ エー／エス Ｐｔｈプロドラッグ
KR20240013849A (ko) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
WO2018129419A1 (en) 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3167644A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
CN113423383A (zh) * 2019-02-11 2021-09-21 阿森迪斯药物骨疾病股份有限公司 Pth缀合物的液体药物制剂
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
EP4110370A4 (en) * 2020-03-30 2023-06-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. FORMULATIONS OF HUMAN PARATHYROID HORMONE (PTH) AND METHODS OF MANUFACTURE THEREOF
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) † 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) † 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
ATE260113T1 (de) 2004-03-15
DK1417972T3 (da) 2013-05-13
NO327302B1 (no) 2009-06-02
JP2001525372A (ja) 2001-12-11
EG23675A (en) 2007-04-15
MY120063A (en) 2005-08-30
EP0920873A3 (en) 1999-08-04
DK1417972T4 (en) 2018-10-22
NO20002945L (no) 2000-07-07
UA72884C2 (ru) 2005-05-16
SK288203B6 (sk) 2014-07-02
CZ302401B6 (cs) 2011-05-04
HUP0004447A3 (en) 2003-06-30
CZ20002115A3 (en) 2001-05-16
DE69821872D1 (de) 2004-04-01
NZ505222A (en) 2003-05-30
CA2314313C (en) 2005-02-08
WO1999029337A1 (en) 1999-06-17
EP0920873B1 (en) 2004-02-25
TW570811B (en) 2004-01-11
DE69821872T2 (de) 2005-01-05
KR20010032881A (ko) 2001-04-25
IL136662A0 (en) 2001-06-14
EA004761B1 (ru) 2004-08-26
PL194268B1 (pl) 2007-05-31
CN1198644C (zh) 2005-04-27
ES2405994T5 (es) 2019-01-30
EP1417972B1 (en) 2013-04-10
EP1417972B2 (en) 2018-08-22
ES2215268T3 (es) 2004-10-01
TR200002134T2 (tr) 2000-11-21
CA2314313A1 (en) 1999-06-17
AU1717799A (en) 2005-05-16
NO20002945D0 (no) 2000-06-08
AR018526A1 (es) 2001-11-28
PT920873E (pt) 2004-06-30
PT1417972E (pt) 2013-05-24
HUP0004447A2 (hu) 2001-04-28
SK15322000A3 (sk) 2001-05-10
EP1417972A1 (en) 2004-05-12
BR9813463A (pt) 2000-10-10
PE20000001A1 (es) 2000-01-17
ES2405994T3 (es) 2013-06-04
EP0920873A2 (en) 1999-06-09
HU230784B1 (en) 2018-05-02
AU759726B2 (en) 2003-04-17
IL136662A (en) 2004-09-27
CN1281370A (zh) 2001-01-24
CY1114000T1 (el) 2016-07-27
ZA9811127B (en) 2000-07-11
DK0920873T3 (da) 2004-06-28
ID27741A (id) 2001-04-26
JP4405666B2 (ja) 2010-01-27
HK1021798A1 (en) 2000-07-07
KR100482703B1 (ko) 2005-04-14
PL340902A1 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
EA200000629A1 (ru) Стабилизированные растворы терипаратида
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
PL329386A1 (en) Growth hormone, amino acid and non-ionic detergent containing pharmaceutic
CA2004598A1 (en) Medicinal aerosol formulations
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EA200100458A1 (ru) Антипаразитарные препараты
IT1219853B (it) Fenil carbammato farmacologicamente attivo,suo procedimento di preparazione e composizione farmaceutica che lo contiene
DE69329651T2 (de) Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält
SE8804629D0 (sv) New therapeutically active compounds
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE69717293T2 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
PT92647A (pt) Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
BR9913699A (pt) Composição inseticida
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
DE69936638D1 (de) Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
EA200200415A1 (ru) Композиция фармацевтического носителя
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
EA200000039A1 (ru) Лечение диабета тиазолидиндионом и сульфонилмочевиной
AR008154A1 (es) Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU